Compare Amgen, Inc. (AMGN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while ABRDN Physical Gold Shares ETF trades at $38.76. The key difference: Amgen, Inc. pays a 2.77% dividend while ABRDN Physical Gold Shares ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SGOL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $388.16 | $51.41 |
52-Week Low | $271.18 | $31.18 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SGOL, a gold-focused US stock, trades at $39.12, down 0.28% on the day amid a broader bearish technical signal. The stock faces headwinds from declining gold prices, which have fallen over 25% from recent highs, and outflows from gold ETFs as investors react to Federal Reserve policy expectations. Despite this, central bank buying provides underlying support, with entities like Poland and China increasing reserves, highlighting a divergence between speculative selling and long-term institutional demand.
The outlook for SGOL remains cautious near-term due to gold price volatility and hawkish Fed sentiment, but structural support from central bank diversification offers a potential floor. Risks include further ETF liquidations and rising Treasury yields, while opportunities lie in sustained institutional accumulation if macroeconomic uncertainty persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
